MarketWatch14hAutomated tone · bullish
Big pharma stocks close near all-time highs as tech selloff pushes investors toward safer betsShares of AbbVie, Eli Lilly and Gilead Sciences closed near record highs
Seeking Alpha1dAutomated tone · bullish
Vir jumps on Gilead licensing deal worth up to $1.9B for cancer drugsYahoo Finance34dAutomated tone · neutral
Gilead Wins Appeals Court Ruling Blocking Imported HIV Drug SalesYahoo Finance42dAutomated tone · bullish
Is Gilead Sciences Stock Outperforming the S&P 500?Seeking Alpha48dAutomated tone · bullish
Gilead once-daily HIV pill approved in U.S.CNBC49dAutomated tone · neutral
FDA approves daily HIV pill from Gilead designed to simplify treatment for some patientsThe new pill is also aimed at people who are doing well on a single-tablet regimen, including Biktarvy, and want to switch to a new treatment.
Yahoo Finance53dAutomated tone · bullish
Gilead’s HIV Business is Surging, but is the Company Too Dependent on One Franchise?Yahoo Finance53dAutomated tone · neutral
Gilead’s Revenue Is Accelerating, But are its Acquisitions Worth the Cost?Yahoo Finance53dAutomated tone · bullish
Pfizer vs. Gilead: Which Drugmaker Has the Stronger Growth Story?Investing.com55dAutomated tone · neutral
Gilead Sciences director Jeffrey Bluestone sells $725,077 in stockGilead Sciences director Jeffrey Bluestone sells $725,077 in stock — See source for full details.
Seeking Alpha57dAutomated tone · bullish
Gilead rises for the seventh straight sessionInvesting.com58dAutomated tone · neutral
Gilead Sciences CFO Andrew Dickinson sells $415k in sharesInvesting.com58dAutomated tone · neutral
Gilead Sciences chief comm & corp aff officer sells $3.85m stockYahoo Finance62dAutomated tone · neutral
Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?CNBC62dAutomated tone · neutral
Court rules companies can't import Gilead medications from overseas in blow to AFP health programsYahoo Finance68dAutomated tone · bullish
Key HIV stat over 70% leaves BofA siding with GileadYahoo Finance71dAutomated tone · neutral
Gilead Slumps As Long-Term Uncertainty Clouds Massive HIV BeatSeeking Alpha72dAutomated tone · neutral
Gilead Sciences declares $0.82 dividendSeeking Alpha72dAutomated tone · bullish
Gilead Sciences in charts: Q2 base sales jump 10% on HIV, oncology growth despite Veklury dropSeeking Alpha72dAutomated tone · bullish
Gilead outlines 2026 base business sales of $29.8B-$30.1B while raising HIV growth outlook to 9%-10%Investing.com72dAutomated tone · bullish
Earnings call transcript: Gilead beats Q2 2026 forecasts, stock eases after hoursInvesting.com72dAutomated tone · bullish
Gilead second-quarter sales rise 8%, beating Wall Street estimatesInvesting.com72dAutomated tone · neutral
Gilead earnings loom: Can Yeztugo, Trodelvy offset acquisition costs?Yahoo Finance72dAutomated tone · bullish
Could Gilead Sciences (GILD) Have a Major HIV Growth Engine in Yeztugo?Investing.com73dAutomated tone · neutral
California’s highest court rules for Gilead, says drugmakers don’t have ’duty to innovate’Seeking Alpha73dAutomated tone · bullish
Gilead wins California high court ruling involving 'duty to innovate' theorySeeking Alpha80dAutomated tone · neutral
ViiV's Dovato as effective as Gilead's Biktarvy in head-to-head trial